Scott Rocklage is preceded by his reputation in healthcare management matters. In fact, his experience in the industry spans more than three decades. Scott serves as a managing partner of 5AM Ventures, a position he took up in 2004 after joining the company in 2003 as a venture partner. He is well-recognized for his strategic leadership roles that resulted in the approval of three new drug applications by the FDA including Cubicin, Teslascan and Omniscan. Additionally, he is also known for initiating the clinical trials of various multiple drug candidates.
Apart from his numerous accomplishments throughout his career, Scott Rocklage has proven to be a well-learned individual. As such, he is an accomplished alumnus of Massachusetts Institute of Technology where he received his Ph.D. in chemistry. Scott conducted his research in the laboratory of the 2005 chemistry Nobel Laureate, Richard R. Schrock. This is in addition to his B.S in chemistry degree from the popular University of California, Berkeley.
As a person with an illustrious career that stretches for over thirty years, Scott Rocklage has served numerous companies in different roles. Previously, he worked as the CEO and chairperson of Cubist Pharmaceuticals. He also served Nycomed Salutar as the company’s CEO and president. Additionally, Scott was the former executive chairman of Miikana (acquired by EntreMed), Ilypsa (acquired by Amgen) and Semprus (acquired by Teleflex).
Scott was a board chairperson for several companies including Relypsa and Novira, which Johnson & Johnson acquired. Currently, he is a chairman of the board of various companies such as Cidara, Kinestral, Pulmatrix, Epirus and Rennovia.
Other Achievements and Roles Played by Scott Rocklage
Aside from demonstrating great leadership skills from one leadership role to the next, Scott has proven to be an outstanding inventor and co-inventor through more than 30 United States patents. He also boasts of more than 100 peer-reviewed publications under his name. According to his Ideamensch interview, he works in close collaboration with various professionals such as physicians and business executives to help them bring ideas to life. By so doing, they can easily convert their ideas into potential treatments that can cure unmet medical issues.